biosimilars
Major Health Plans Will Prefer Humira Biosimilars in 2025
The market dominance of Humira may finally be at an end, as payors make dramatic shifts in favor of biosimilars to ...
DECEMBER 12, 2024
New AGA Living Guideline Expands Recommended Drugs for Moderate to Severe UC
The AGA has released a new, updated guideline on pharmacologic management of adult outpatients with ulcerative ...
NOVEMBER 26, 2024
Patients Report Satisfaction Switching From Infliximab to Biosimilars
Most patients with IBD who switch from infliximab to an infliximab biosimilar report a positive experience, ...
OCTOBER 29, 2024
IBD Clinical Trials at a Crossroads
Inflammatory bowel disease clinical trials are facing headwinds, with challenges in recruitment and trial design.
OCTOBER 22, 2024
FDA Approves Fourth Ustekinumab Biosimilar, Otulfi
The FDA has approved ustekinumab-aauz (Otulfi, Fresenius Kabi/Formycon), a biosimilar to ustekinumab (Stelara, ...
OCTOBER 7, 2024
FDA Approves Pyzchiva Biosimilar to Stelara
Pyzchiva was approved for all indications of its reference biologic; the FDA provisionally determined that ...
JULY 3, 2024
New FDA Approvals Increase Variety in Field of Adalimumab Biosimilars
New FDA approvals of adalimumab biosimilars are bringing more choice to prescribers.
MAY 25, 2023
FDA Approves Citrate-Free Formulation of Hyrimoz, a Biosimilar to Humira
The FDA approved a citrate-free high-concentration formulation of Hyrimoz injection, a biosimilar to Humira.
MARCH 31, 2023
Amjevita, First Biosimilar to Humira Launches
Adalimumab-atto, an anti-tumor necrosis factor-alpha monoclonal antibody is the first biosimilar to Humira to ...
FEBRUARY 2, 2023
Report From CCC 2023: Switching to Infliximab Biosimilar Safe for Adolescents, Young Adults With IBD
Adolescents and young adults with inflammatory bowel disease can switch from the originator to a biosimilar of ...
JANUARY 20, 2023
FDA Approves New Formula for Hadlima, Biosimilar to Humira
The FDA approved a citrate-free, high-concentration (100 mg/mL) formulation of HADLIMA, a biosimilar referencing ...
AUGUST 23, 2022
FDA Grants Cyltezo Biosimilar ‘Interchangeable’ Status
The FDA has expanded the designation of adalimumab-adbm (Cyltezo, Boehringer Ingelheim) to include interchangeable ...
OCTOBER 19, 2021
